Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension

Information

• Research Project
• 9710983

• ApplicationId

  9710983

• Core Project Number

  R44HL140690

• Full Project Number

  4R44HL140690-02

• Serial Number

  140690

• FOA Number

  PA-16-302

• Sub Project Id

• Project Start Date

  2/17/2018 - 6 years ago

• Project End Date

  7/31/2020 - 4 years ago

• Program Officer Name

  XIAO, LEI

• Budget Start Date

  8/1/2018 - 6 years ago

• Budget End Date

  7/31/2019 - 5 years ago

• Fiscal Year

  2018

• Support Year

  02

• Suffix

• Award Notice Date

  7/31/2018 - 6 years ago

Organizations

• PhaseBio Pharmaceuticals, Inc.

IC Name

• Activity

  R44

• Administering IC

  HL

• Application Type

  4

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  1247966

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  838

• Ed Inst. Type

• Funding ICs

  NHLBI:1247966\

• Funding Mechanism

  SBIR-STTR RPGs

• Study Section

  ZRG1

• Study Section Name

  Special Emphasis Panel

• Organization Name

  PHASEBIO PHARMACEUTICALS, INC.

• Organization Department

• Organization DUNS

  126104244

• Organization City

  MALVERN

• Organization State

  PA

• Organization Country

  UNITED STATES

• Organization Zip Code

  193551423

• Organization District

  UNITED STATES